Your session is about to expire
← Back to Search
Other
AIV007 Treatment Dose 3 for Age-Related Macular Degeneration
Phase 1
Waitlist Available
Research Sponsored by AiViva BioPharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 224 days
Awards & highlights
Summary
This trial is testing a special gel injected into the eye for patients with a severe eye condition called neovascular age-related macular degeneration. The gel releases medicine slowly to help manage the disease.
Eligible Conditions
- Age-Related Macular Degeneration
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 224 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 224 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adverse Events
Secondary outcome measures
Mean change from baseline in BCVA
Mean change from baseline in central subfield thickness as measured by optical coherence tomography
Mean time to escape medication
Trial Design
3Treatment groups
Experimental Treatment
Group I: AIV007 Treatment Dose 3Experimental Treatment1 Intervention
Intravitreal, Dose 3
Group II: AIV007 Treatment Dose 2Experimental Treatment1 Intervention
Intravitreal, Dose 2
Group III: AIV007 Treatment Dose 1Experimental Treatment1 Intervention
Intravitreal, Dose 1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AIV007
2020
Completed Phase 1
~10
Find a Location
Who is running the clinical trial?
AiViva BioPharma, Inc.Lead Sponsor
5 Previous Clinical Trials
97 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger